NCT01076335View on ClinicalTrials.gov

Neoadjuvant Hormones + Docetaxel in Node-Positive Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Prostate Cancer
Interventions
DRUG

Neoadjuvant Hormonal Therapy

Monthly or quarterly LHRH Agonist Depot injection (leuprolide or goserelin acetate) for one year.

DRUG

Docetaxel

35 mg/m2 by vein (IV) on Day 1, 8, 15 and 22 every 6 weeks.

Trial Locations (1)

77007

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT01076335 - Neoadjuvant Hormones + Docetaxel in Node-Positive Prostate Cancer | Biotech Hunter | Biotech Hunter